Serum - Protection from birth onwards
Serum Institute of India has initiated development of acellular pertussis vaccine containing purified antigenic components of B. Pertussis viz. Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin.
The DTaP vaccine that is under development at Serum Institute of India is being tested at NIBSC, UK and is undergoing toxicology studies. Serum Institute of India plans to develop this product for the people of the developing world within next two years. DTP vaccines in the near future will have combinations of other components and the key antigen for such combinations will be acellular pertussis component.
R21 is recombinant fusion protein comprises P. falciparum circumsporozoite protein fused with hepatitis B surface antigen & expressed as virus-like particles (VLPs) in recombinant yeast produced in Hansenula polymorpha. Introduction of this vaccine will significantly bring down the mortality in Malaria endemic countries more specifically in sub-Saharan Africa.